Stock & Company Details
Cabaletta Bio Inc $CABA
Price:
46,691,331
163M
$439M
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
0.00
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
Health Technology
CABA technical indicators
Latest Cabaletta Bio Inc (CABA) technical indicators as of 2026-07-27: RSI, MACD, moving averages (SMA & EMA), Bollinger Bands, Stochastic, ADX, ATR, CCI, OBV and ROC.
RSI 14:
41.24 3.9%
MACD:
-0.12 1.8%
SMA 50:
$3.14 0.6%
SMA 200:
$2.86 0.1%
EMA 20:
$2.86 0.5%
Bollinger Bands:
3.25 / 2.54
Stochastic:
17.65 3.0%
ADX 14:
20.09 0.7%
ATR 14:
0.20 1.8%
CCI 20:
-64.43 28.3%
OBV:
147.37M 1.5%
ROC 12:
-12.82% 8.8%
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
Finance Bot
Ask your questions
Start by typing a question below.
